|
2025-05-14 |
2025-05-12 |
PS
Planned sale
|
Birkemeyer Elaine M.
Chief Financial Officer
Officer
|
2,921
-2.9%
9.94
USD 29,037
|
2,921
-2.9%
|
9.94
|
USD 29,037
|
|
|
2025-05-12 |
2025-05-08 |
S
Sale
|
Dodd Sheri Louise
Chief Executive Officer
Executive Director
|
3,149
-1.7%
9.83
USD 30,955
|
3,149
-1.7%
|
9.83
|
USD 30,955
|
|
|
2025-05-09 |
2025-05-08 |
PS
Planned sale
|
BURKE WILLIAM W
Non-Executive Director
|
3,300
-6.4%
9.67
USD 31,911
|
3,300
-6.4%
|
9.67
|
USD 31,911
|
|
|
2025-02-27 |
2025-02-25 |
PS
Planned sale
|
REUVERS DANIEL L.
Non-Executive Director
|
28,338
-11.7%
14.18
USD 401,850
|
28,338
-11.7%
|
14.18
|
USD 401,850
|
|
|
2025-02-27 |
2025-02-25 |
S
Sale
|
Burns Kristie
Sr. VP Mktg & Clinical Affairs
Officer
|
6,468
-7.7%
14.40
USD 93,160
|
6,468
-7.7%
|
14.40
|
USD 93,160
|
|
|
2025-02-27 |
2025-02-25 |
PS
Planned sale
|
Birkemeyer Elaine M.
Chief Financial Officer
Officer
|
2,066
-2.0%
14.51
USD 29,980
|
2,066
-2.0%
|
14.51
|
USD 29,980
|
|
|
2025-02-24 |
2025-02-24 |
PS
Planned sale
|
REUVERS DANIEL L.
Non-Executive Director
|
10,938
-4.3%
14.55
USD 159,147
|
10,938
-4.3%
|
14.55
|
USD 159,147
|
|
|
2025-02-24 |
2025-02-24 |
PS
Planned sale
|
Birkemeyer Elaine M.
Chief Financial Officer
Officer
|
3,778
-3.5%
14.70
USD 55,538
|
3,778
-3.5%
|
14.70
|
USD 55,538
|
|
|
2025-02-24 |
2025-02-24 |
S
Sale
|
Burns Kristie
Sr. VP Mktg & Clinical Affairs
Officer
|
4,830
-5.4%
14.65
USD 70,753
|
4,830
-5.4%
|
14.65
|
USD 70,753
|
|
|
2024-08-14 |
2024-08-12 |
S
Sale
|
Ferstler Sherri Lee
Senior VP, Sales
Officer
|
1,550
-3.8%
13.07
USD 20,263
|
1,550
-3.8%
|
13.07
|
USD 20,263
|
|
|
2024-05-20 |
2024-05-16 |
S
Sale
|
Birkemeyer Elaine M.
Chief Financial Officer
Officer
|
3,041
-4.7%
13.68
USD 41,590
|
3,041
-4.7%
|
13.68
|
USD 41,590
|
|
|
2024-05-10 |
2024-05-08 |
PS
Planned sale
|
BURKE WILLIAM W
Non-Executive Director
|
2,500
-9.0%
14.06
USD 35,150
|
2,500
-9.0%
|
14.06
|
USD 35,150
|
|
|
2024-05-08 |
2024-05-06 |
S
Sale
|
Burns Kristie
Sr. VP Mktg & Clinical Affairs
Officer
|
815
-1.3%
14.37
USD 11,713
|
815
-1.3%
|
14.37
|
USD 11,713
|
|
|
2024-02-29 |
2024-02-29 |
PS
Planned sale
|
REUVERS DANIEL L.
President and CEO
Executive Director
|
1,396
-0.6%
15.25
USD 21,289
|
1,396
-0.6%
|
15.25
|
USD 21,289
|
|
|
2024-02-29 |
2024-02-29 |
PS
Planned sale
|
Burns Kristie
Sr. VP Mktg & Clinical Affairs
Officer
|
243
-0.4%
15.25
USD 3,706
|
243
-0.4%
|
15.25
|
USD 3,706
|
|
|
2024-02-29 |
2024-02-27 |
PS
Planned sale
|
REUVERS DANIEL L.
President and CEO
Executive Director
|
4,689
-1.9%
15.60
USD 73,148
|
4,689
-1.9%
|
15.60
|
USD 73,148
|
|
|
2024-02-29 |
2024-02-27 |
PS
Planned sale
|
Burns Kristie
Sr. VP Mktg & Clinical Affairs
Officer
|
1,091
-1.7%
15.58
USD 17,001
|
1,091
-1.7%
|
15.58
|
USD 17,001
|
|
|
2024-02-27 |
2024-02-26 |
PS
Planned sale
|
Burns Kristie
Sr. VP Mktg & Clinical Affairs
Officer
|
2,015
-3.1%
15.91
USD 32,049
|
2,015
-3.1%
|
15.91
|
USD 32,049
|
|
|
2024-02-27 |
2024-02-26 |
PS
Planned sale
|
REUVERS DANIEL L.
President and CEO
Executive Director
|
6,239
-2.5%
15.81
USD 98,645
|
6,239
-2.5%
|
15.81
|
USD 98,645
|
|
|
2024-02-27 |
2024-02-23 |
PS
Planned sale
|
Burns Kristie
Sr. VP Mktg & Clinical Affairs
Officer
|
2,249
-4.0%
14.80
USD 33,278
|
2,249
-4.0%
|
14.80
|
USD 33,278
|
|
